-transparent.png){kind=logo}
Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein. 1996
S Bertagnoli, and
J Gelfi, and
G Le Gall, and
E Boilletot, and
J F Vautherot, and
D Rasschaert, and
S Laurent, and
F Petit, and
C Boucraut-Baralon, and
A Milon
Laboratoire Associé de Microbiologie Moléculaire, Institut National de la Recherche Agronomique and Ecole Nationale Vétérinaire, Toulouse, France.
Two myxoma virus-rabbit hemorrhagic disease virus (RHDV) recombinant viruses were constructed with the SG33 strain of myxoma virus to protect rabbits against myxomatosis and rabbit viral hemorrhagic disease. These recombinant viruses expressed the RHDV capsid protein (VP60). The recombinant protein, which is 60 kDa in size, was antigenic, as revealed by its reaction in immunoprecipitation with antibodies raised against RHDV. Both recombinant viruses induced high levels of RHDV- and myxoma virus-specific antibodies in rabbits after immunization. Inoculations by the intradermal route protected animals against virulent RHDV and myxoma virus challenges.
Related Publications
S Bertagnoli, and
J Gelfi, and
G Le Gall, and
E Boilletot, and
J F Vautherot, and
D Rasschaert, and
S Laurent, and
F Petit, and
C Boucraut-Baralon, and
A Milon
February 2000,
Journal of virology,
S Bertagnoli, and
J Gelfi, and
G Le Gall, and
E Boilletot, and
J F Vautherot, and
D Rasschaert, and
S Laurent, and
F Petit, and
C Boucraut-Baralon, and
A Milon
September 2000,
Vaccine,
S Bertagnoli, and
J Gelfi, and
G Le Gall, and
E Boilletot, and
J F Vautherot, and
D Rasschaert, and
S Laurent, and
F Petit, and
C Boucraut-Baralon, and
A Milon
November 2019,
Vaccines,
S Bertagnoli, and
J Gelfi, and
G Le Gall, and
E Boilletot, and
J F Vautherot, and
D Rasschaert, and
S Laurent, and
F Petit, and
C Boucraut-Baralon, and
A Milon
January 2018,
Veterinary microbiology,
S Bertagnoli, and
J Gelfi, and
G Le Gall, and
E Boilletot, and
J F Vautherot, and
D Rasschaert, and
S Laurent, and
F Petit, and
C Boucraut-Baralon, and
A Milon
October 1994,
Journal of virology,
S Bertagnoli, and
J Gelfi, and
G Le Gall, and
E Boilletot, and
J F Vautherot, and
D Rasschaert, and
S Laurent, and
F Petit, and
C Boucraut-Baralon, and
A Milon
June 2002,
Vaccine,
S Bertagnoli, and
J Gelfi, and
G Le Gall, and
E Boilletot, and
J F Vautherot, and
D Rasschaert, and
S Laurent, and
F Petit, and
C Boucraut-Baralon, and
A Milon
January 1995,
Veterinary research,
S Bertagnoli, and
J Gelfi, and
G Le Gall, and
E Boilletot, and
J F Vautherot, and
D Rasschaert, and
S Laurent, and
F Petit, and
C Boucraut-Baralon, and
A Milon
August 2001,
Vaccine,
S Bertagnoli, and
J Gelfi, and
G Le Gall, and
E Boilletot, and
J F Vautherot, and
D Rasschaert, and
S Laurent, and
F Petit, and
C Boucraut-Baralon, and
A Milon
May 1999,
Journal of virology,
S Bertagnoli, and
J Gelfi, and
G Le Gall, and
E Boilletot, and
J F Vautherot, and
D Rasschaert, and
S Laurent, and
F Petit, and
C Boucraut-Baralon, and
A Milon
February 2022,
Vaccines,
